Mabylon AG, a private Swiss biotech company, is leading innovation in antibody-based treatments for severe allergies, inflammation, and neurological disorders. Our B-cell screening platform identifies natural human antibodies with high specificity and therapeutic potential. MY006, our first-in-class multispecific antibody therapeutic for peanut allergy, is tackling the growing food allergy market.

Biotechnology

Health Care

Health Data

Life Sciences

Mabylon AG

Mabylon AG's headquarters in Schlieren, Switzerland

Description

People (6)

Dimitri Bieli

Chiara Arena

Nikole Z.

Doug Phillips

Bettina Mathis

Pascal G.

Jobs